Activity of Daptomycin against Recent North American Isolates of Streptococcus pneumoniae

ABSTRACT Daptomycin MICs at which 50% of isolates were inhibited (MIC50s) and MIC90s determined by the NCCLS broth microdilution method were both 0.25 μg/ml (range, 0.06 to 2 μg/ml) for 350 pneumococcal isolates. MICs determined by E test strips on commercially prepared Mueller-Hinton sheep blood agars with different calcium contents were 2 to 3 dilutions higher than those determined by strips that contained daptomycin plus calcium. Daptomycin zone diameters varied little on the same media.

[1]  E. Goldstein,et al.  In Vitro Activities of Daptomycin, Vancomycin, Quinupristin- Dalfopristin, Linezolid, and Five Other Antimicrobials against 307 Gram-Positive Anaerobic and 31 Corynebacterium Clinical Isolates , 2003, Antimicrobial Agents and Chemotherapy.

[2]  P. Bradford,et al.  In Vitro and In Vivo Activities of Tigecycline (GAR-936), Daptomycin, and Comparative Antimicrobial Agents against Glycopeptide-Intermediate Staphylococcus aureus and Other Resistant Gram-Positive Pathogens , 2002, Antimicrobial Agents and Chemotherapy.

[3]  Xilin Zhao,et al.  Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. , 2002, The New England journal of medicine.

[4]  Susan R. Johnson,et al.  Macrolide Resistance among Invasive Streptococcus Pneumoniae Isolates , 2022 .

[5]  A. Barry,et al.  Evaluation of daptomycin susceptibility testing by Etest and the effect of different batches of media. , 2001, The Journal of antimicrobial chemotherapy.

[6]  Steven D. Brown,et al.  In Vitro Activities of Daptomycin against 2,789 Clinical Isolates from 11 North American Medical Centers , 2001, Antimicrobial Agents and Chemotherapy.

[7]  J. Karlowsky,et al.  Need for Annual Surveillance of Antimicrobial Resistance in Streptococcus pneumoniae in the United States: 2-Year Longitudinal Analysis , 2001, Antimicrobial Agents and Chemotherapy.

[8]  V. Cheng,et al.  Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  M. Cetron,et al.  Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. , 2000, The New England journal of medicine.

[10]  D. Snydman,et al.  Comparative In Vitro Activities of Daptomycin and Vancomycin against Resistant Gram-Positive Pathogens , 2000, Antimicrobial Agents and Chemotherapy.

[11]  P. Gilligan,et al.  Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  F. Tally,et al.  Development of daptomycin for gram-positive infections. , 2000, The Journal of antimicrobial chemotherapy.

[13]  Michael J Fine,et al.  Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  A. Schuchat,et al.  Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. , 2000, Archives of internal medicine.

[15]  A. Schuchat,et al.  Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. , 2000, American journal of public health.

[16]  D. Sahm,et al.  Survey of Susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis Isolates to 26 Antimicrobial Agents: a Prospective U.S. Study , 1999, Antimicrobial Agents and Chemotherapy.

[17]  G. Doern,et al.  Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997 98. , 1999, Emerging infectious diseases.

[18]  D E Low,et al.  Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. , 1999, The New England journal of medicine.

[19]  T. Ng,et al.  Emergence of Fluoroquinolone Resistance among Multiply Resistant Strains of Streptococcus pneumoniae in Hong Kong , 1999, Antimicrobial Agents and Chemotherapy.

[20]  M. Cetron,et al.  The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System. , 1996, The Journal of infectious diseases.

[21]  J. Martínez-Suárez,et al.  Comparative in-vitro activity of four peptide antibiotics against penicillin-resistant Streptococcus pneumoniae isolated from cerebrospinal fluid (CSF). , 1992, The Journal of antimicrobial chemotherapy.

[22]  W. Alborn,et al.  Daptomycin disrupts membrane potential in growing Staphylococcus aureus , 1991, Antimicrobial Agents and Chemotherapy.

[23]  L. Nilsson,et al.  Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs , 1991, Antimicrobial Agents and Chemotherapy.

[24]  M. Jacobs,et al.  Susceptibility of penicillin-sensitive and -resistant strains of Streptococcus pneumoniae to new antimicrobial agents, including daptomycin, teicoplanin, cefpodoxime and quinolones. , 1989, The Journal of antimicrobial chemotherapy.

[25]  J. Lakey,et al.  Fluorescence indicates a calcium-dependent interaction between the lipopeptide antibiotic LY146032 and phospholipid membranes. , 1988, Biochemistry.

[26]  J. Jorgensen,et al.  In vitro activity of LY146032 (Daptomycin) against selected aerobic bacteria , 1987, European Journal of Clinical Microbiology.

[27]  M. Ferraro.  Performance standards for antimicrobial susceptibility testing , 2001 .

[28]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[29]  G. Doern,et al.  Antimicrobial Resistance with Streptococcus Pneumoniae in the United States , 2000, Seminars in respiratory and critical care medicine.

[30]  Oyce,et al.  DECREASED SUSCEPTIBILITY OF STREPTOCOCCUS PNEUMONIAE TO FLUOROQUINOLONES IN CANADA , 2000 .